Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Nat Rev Cancer. 2008 Apr;8(4):268-78. doi: 10.1038/nrc2351.

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.

Author information

  • 1Department of Surgery (Urology), Memorial Sloan-Kettering Cancer Center New York, New York 10065, USA. liljah@mskcc.org

Erratum in

  • Nat Rev Cancer. 2008 May;8(5):403.

Abstract

Testing for prostate-specific antigen (PSA) has profoundly affected the diagnosis and treatment of prostate cancer. PSA testing has enabled physicians to detect prostate tumours while they are still small, low-grade and localized. This very ability has, however, created controversy over whether we are now diagnosing and treating insignificant cancers. PSA testing has also transformed the monitoring of treatment response and detection of disease recurrence. Much current research is directed at establishing the most appropriate uses of PSA testing and at developing methods to improve on the conventional PSA test.

PMID:
18337732
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk